Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin Versus Heparin in Anticoagulant Therapy of ECMO
NCT06275555Recruiting
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of bivalirudin in extracorporeal membrane oxygenation complication (2 arms). Primary endpoints: Incidence of thrombotic complications at 7 days and Incidence of bleeding complications at 7 days. Started Jun 2024; status: recruiting.
02
Drugs
bivalirudin
03
Conditions
extracorporeal membrane oxygenation complication
Beyond the preview
Go deeper on NCT06275555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06275555.